RxDoctor Payments Data

Jibran Rana, MD

Interventional Cardiology · Rockford, ILNPI 1043638729

Payments from drug & device makers

$9,424in general payments, 2019–2025

Across 90 payments — averaging $104.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Edwards Lifesciences$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$844
  • Boston Scientific$656
  • Shockwave Medical, Inc$608
  • Medtronic$465
  • plus $2K from 17 others

What the payments were for

  • Grants$3494%
  • Travel & lodging$2,80730%
  • Food & beverage$5,50858%
  • Education$7618%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,424 in reported general payments places this provider in the 50th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$33,649
Medicare patients
122
Services billed
341

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab19$27,908
EliquisApixaban21$21,397
BrilintaTicagrelor14$15,900
EntrestoSacubitril/Valsartan22$14,358
Metoprolol Succinate62$747
Ezetimibe45$503
Atorvastatin Calcium77$407
Rosuvastatin Calcium56$362
ClopidogrelClopidogrel Bisulfate35$322
Nifedipine ErNifedipine12$322
Amlodipine Besylate43$196
Lisinopril43$195
Metoprolol Tartrate30$155
Carvedilol23$151
Chlorthalidone12$139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$195$15,90014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Rockford

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →